| Summary: | Background: Metabolic syndrome is often associated as a major risk factor for cardiovascular disease and increases risk for type 2 diabetes mellitus. The pathogenesis of the metabolic syndrome and each of its components is complex and not well understood. However, central obesity and insulin resistance are widely accepted and acknowledged by many studies as important causative factors.
Aim: The study was aimed at exploring whether metformin and valsartan in combination can help improve central obesity, thus reducing the waist circumference of the patient.
Method: The research design was one group pre test- post test design of a quasi experiment. 22 patients who were under treatment at the internal medicine endocrinology polyclinic of Dr. Sardjito Hospital, Yogyakarta were recruited as subjects. The change of waist circumference at the end of 12 weeks of drug intervention was evaluated using paired- sample T test.
Results: The result revealed that metformin and valsartan increased the waist circumference by 0,750± 3,497, as opposed to the hypothesis (P= 0,326).
Conclusion: Metformin and valsartan therapy increase the waist circumference of patient with metabolic syndrome. However, the result is insignificant.
|
|---|